Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Two new studies in mice have shown that disrupting the microbial balance in the gut through the use of antibiotics can affect the response to cancer therapy.
Five recent papers have looked more closely at mechanisms that underlie resistance to inhibitors of the ERK MAPK pathway in melanomas that have the BRAF-V600E mutation and have shown that several mechanisms probably contribute to resistance, even within the same patient.
Cancer of unknown primary site is both a challenging clinical problem and a disease that provides potential insight into the mechanisms that underlie early metastasis.
A paper inNaturereports the design of small molecules that can irreversibly bind to and block the activity of oncogenic KRAS-G12C, but not wild-type KRAS.
A new study by Emerling and colleagues has shown that phosphatidylinositol 5-phosphate 4-kinase type-2α (PIP4K2α) and PIP4K2β are essential for the growth of p53-null cells and may represent a pharmaceutical target for cancers that have non-functional p53.
Although survival rates for most paediatric cancers have improved at a remarkable pace over the past four decades, the vast majority of these cancer survivors will have at least one chronic health condition by 40 years of age. How can we best understand and treat the long-term morbidity and mortality that is associated with currently successful treatments?